ClinicalTrials.gg
RecruitingNCT05125302Ubro PedsUpdated Sep 14, 2026

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

A Phase 3 interventional study of Ubrogepant and Placebo-Matching Ubrogepant in Migraine, sponsored by AbbVie. Recruiting at 129 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,059
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Planned enrollment
5th of 14
1,059 · median 507
Started
2022
with 4 others
Phase 3
7 of 14
2 open now
Registered
9th of 14
by date
Lead sponsor
6 of 14
AbbVie

Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 5th largest by planned enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 9th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents.

Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (aged 6-17 years) with a history of migraine will be enrolled. The study will include 2 cohorts of participants - PK Cohort and Main Study (non-PK cohort). Participants aged 6-11 years in the PK Cohort will receive Dose A or Dose B of Ubrogepant for PK analysis to determine dose selection for the main study. In the main study, after dose selection, children aged 6-11 years will be randomized to receive either low or high dose of Ubrogepant or placebo. There is a 1 in 3 chance that a participant will be assigned to placebo. Adolescents aged 12-17 years will be randomized to receive either low or high dose of Ubrogepant or placebo with a 1 in 3 chance of placebo assignment.

For qualifying migraine attacks, participants will receive oral tablets of the double-blind study intervention. There will be an option to take a second dose of double-blind study intervention (identical to initial dose), or rescue medication, at least 2 hours after the initial dose, for headache of moderate/severe intensity. Around 1059 participants will be enrolled in the study in approximately 120 sites in the United States. The study duration will be up to 6 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
  • Ubrogepant
  • Ubrelvy
  • PERISCOPE
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD-3) for at least 6 months.
  • By history, the participant's migraines typically last between 3 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom.
  • History of 1 to 14 migraine attacks per month with moderate to severe headache in each of the 2 months prior to screening (Visit 1).
  • Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.
  • For main study participants, treatment of a qualifying migraine with single-blind placebo during the screening period and completion of 2-hour headache pain assessment.
  • Weight is ≥ 20 kg (44 pounds) and \< 135 kg (298 pounds)
  • Per investigator judgment, participant is able to swallow or can learn to swallow study intervention.
  • The participant is able to understand and complete the study questionnaires and eDiary. Participants who need assistance with reading the assessments may be assisted by a parent or guardian.

Exclusion criteria

Exclusion Criteria:

  • Any hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease.
  • In the opinion of the investigator, other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.
  • History of in the 5 years prior to Visit 1.
  • History of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of the study intervention.
  • Significant risk of self-harm, based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale (C-SSRS), or of harm to others; participants must be excluded if they report suicidal ideation with intent, with or without a plan, (ie, Type 4 or 5 on the C-SSRS) in the past 6 months or report suicidal behavior in the last 6 months prior to Visit 1 or Visit 2 assessments.
  • At Visit 1, current alcohol or drug abuse or dependence per investigator's judgment.
  • For main study participants, no headache at the 2-hour post dose assessment after taking single-blind placebo for a qualifying migraine during screening period (ie, placebo responder).
  • A current diagnosis of chronic migraine as defined by ICHD-3
  • Participants who overuse medication for migraine defined as use of opioids or barbiturates > 2 days/month, triptans or ergots ≥ 10 days/month, simple analgesics (eg, aspirin, NSAIDs, acetaminophen) ≥ 15 days/month or any combination of triptans, ergots, or simple analgesics (eg, aspirin, NSAIDs, acetaminophen) ≥ 10 days/month in the 3 months prior to Visit 1 per investigator's judgment.
  • Difficulty distinguishing migraine headache from tension-type or other headaches.
  • Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine as defined by ICHD-3.
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3
  • Required in-hospital (excluding emergency department visits) treatment for migraines 3 or more times in the 6 months prior to Visit 1.
  • Requirement for any medication (eg, barbiturates) or diet (eg, grapefruit juice) that is on the list of prohibited concomitant medications that cannot be discontinued or switched to an allowable, alternative medication at Visit 1.
  • Previous exposure, within the last 6 months, to injectable monoclonal antibodies blocking the calcitonin gene-related peptide (CGRP) pathway
  • History of or clinically significant adverse reaction to a CGRP receptor antagonist or hypersensitivity to any component of the study interventions, ubrogepant or placebo.
  • Currently participating or has participated in a study with an compound or device within 30 days prior to Visit 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,059 participants (estimated)

Study arms

  • Experimental
    PK Cohort: Ubrogepant Dose A

    Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.

    Drug: Ubrogepant

  • Experimental
    PK Cohort: Ubrogepant Dose B

    Participants aged 6 to 11 will receive oral tablets of ubrogepant for PK analysis to determine appropriate dose for main study.

    Drug: Ubrogepant

  • Experimental
    Main Study: Children Ubrogepant Low Dose

    Participants aged 6 to 11 (after dose selection) will receive oral tablets of low dose ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

    Drug: Ubrogepant

  • Experimental
    Main Study: Children Ubrogepant High Dose

    Participants aged 6 to 11 (after dose selection) will receive oral tablets of high dose ubrogepant Dose B for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

    Drug: Ubrogepant

  • Placebo comparator
    Main Study: Children Ubrogepant Placebo

    Participants aged 6 to 11 (after dose selection) will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

    Drug: Placebo-Matching Ubrogepant

  • Experimental
    Main Study: Adolescents Ubrogepant Low Dose

    Participants aged 12 to 17 will receive oral tablets of ubrogepant low dose for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

    Drug: Ubrogepant

  • Experimental
    Main Study: Adolescents Ubrogepant High Dose

    Participants aged 12 to 17 will receive oral tablets of ubrogepant high dose or qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

    Drug: Ubrogepant

  • Placebo comparator
    Main Study: Adolescents Ubrogepant Placebo

    Participants aged 12 to 17 will receive oral tablets of placebo-matching ubrogepant for qualifying migraine attack. Participants have the option to take a second dose of placebo-matching ubrogepant or rescue medication, starting 2 hours after initial dose for headache of moderate/severe intensity.

    Drug: Placebo-Matching Ubrogepant

Interventions

  • Oral Tablet

    Also known as: Ubrelvy

  • DrugPlacebo-Matching Ubrogepant

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.

    Time frame: 2 hours after initial dose

Secondary outcomes

  1. Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 12 to 17 years

    Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to

    Time frame: 2 hours after initial dose

  2. Percentage of participants with Pain Relief at 2 Hours After the Initial Dose in pediatric participants aged 12 to 17 years

    Pain Relief is defined as a reduction in headache severity from moderate/severe at baseline to mild or no pain.

    Time frame: 2 hours after initial dose

  3. Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose in pediatric participants aged 6 to 17 years

    Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug.

    Time frame: 2 to 24 hours after initial dose

  4. Percentage of participants that used rescue medication (including a second dose of study intervention) within 24 hours after the initial dose in pediatric participants aged 6 to 17 years

    Time frame: 24 hours after initial dose

  5. Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose in pediatric participants aged 6 to 17 years

    The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'.

    Time frame: Baseline (Predose) to 2 hours after initial dose

  6. Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose in pediatric participants aged 12 to 17 years

    The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'.

    Time frame: Baseline (Predose) to 2 hours after initial dose

  7. Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 11 years

    Pain Freedom is defined as a reduction in headache severity from moderate/severe at baseline to no pain.

    Time frame: 2 hours after initial dose

  8. Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Photophobia was defined as sensitivity to light, a migraine-associated symptom.

    Time frame: 2 hours after initial dose

  9. Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Phonophobia was defined as sensitivity to sound, a migraine-associated symptom.

    Time frame: 2 hours after initial dose

  10. Percentage of Participants With the Absence of Nausea at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years

    Nausea was a migraine-associated symptom.

    Time frame: 2 hours after initial dose

  11. Number of Participants with Adverse Events (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 6 months

  12. Percentage of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed in pediatric participants aged 6 to 17 years

    Percentage of participants with abnormal change in clinical laboratory test results like hematology will be assessed.

    Time frame: Up to 6 months

  13. Change From Baseline in Electrocardiograms (ECGs) in pediatric participants aged 6 to 17 years

    12-lead resting ECGs will be recorded. Parameters include heart rate, PR interval, QT interval, QRS duration, and QT interval corrected using Fridericia's formula (QTcF).

    Time frame: Up to 6 months

  14. Percentage of Participants with Abnormal Change From Baseline in Vital Sign Measurements in pediatric participants aged 6 to 17 years

    Percentage of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.

    Time frame: Up to 6 months

  15. Percentage of patients with suicidal ideation or suicidal behavior

    Time frame: Up to 6 months

07

Study locations

91 of 129 sites recruiting
  • Rehabilitation & Neurological Services /ID# 229969
    Huntsville, Alabama 35805-4046, United States
    Recruiting
  • The Center for Clinical Trials - Saraland /ID# 231546
    Saraland, Alabama 36571, United States
    Recruiting
  • Velocity Clinical Research - Phoenix /ID# 274478
    Phoenix, Arizona 85006, United States
    Recruiting
  • HealthStar Research Glenwood /ID# 275303
    Glenwood, Arkansas 71943, United States
    Recruiting
  • HealthStar Research of Hot Springs /ID# 273256
    Hot Springs, Arkansas 71913, United States
    Recruiting
    • Site Coordinator · Contact501-760-2903
  • Preferred Research Partners /ID# 230725
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Advanced Research Center /ID# 227962
    Anaheim, California 92805, United States
    Recruiting
  • Neuro Pain Research Center /ID# 227966
    Fresno, California 93710, United States
    Recruiting
  • Imax Clinical Trials /ID# 281436
    La Palma, California 90623, United States
    Recruiting
    • Site Coordinator · Contact(714) 735-8100
  • Alliance for Research Alliance for Wellness /ID# 230546
    Long Beach, California 90807, United States
    Recruiting
  • Children's Hospital Los Angeles /ID# 230596
    Los Angeles, California 90027, United States
    Completed

    Not enrolling at this site — choose another above.

  • Paradigm Clinical Research - Modesto, CA /ID# 280611
    Modesto, California 95355, United States
    Recruiting
  • Excell Research, Inc /ID# 230899
    Oceanside, California 92056, United States
    Recruiting
  • Paradigm Clinical Research - San Diego /ID# 269608
    San Diego, California 92108-1681, United States
    Recruiting
    • Site Coordinator · Contact858-274-4226
  • Lumos Clinical Research Center /ID# 231267
    San Jose, California 95124-4108, United States
    Recruiting
  • Pacific Clinical Research Management Group /ID# 231636
    Upland, California 91786, United States
    Completed

    Not enrolling at this site — choose another above.

  • Sunwise Clinical Research /ID# 230971
    Walnut Creek, California 94596, United States
    Recruiting
  • Amicis Research Center /ID# 272621
    Winnetka, California 91306, United States
    Recruiting
    • Site Coordinator · Contact818-924-4708
  • Paradigm Clinical Research - Aurora, CO /ID# 280612
    Aurora, Colorado 80012, United States
    Recruiting
  • Children's Hospital Colorado - Aurora /ID# 231879
    Aurora, Colorado 80045, United States
    Recruiting
  • IMMUNOe Research Centers /ID# 230879
    Centennial, Colorado 80112, United States
    Completed

    Not enrolling at this site — choose another above.

  • MCB Clinical Research Centers - Colorado Springs - South Parkside Drive /ID# 231625
    Colorado Springs, Colorado 80910, United States
    Completed

    Not enrolling at this site — choose another above.

  • New England Institute for Clinical Research /ID# 230635
    Stamford, Connecticut 06905, United States
    Recruiting
  • Emerson Clinical Research Institute - Connecticut Avenue - Washington /ID# 231693
    Washington D.C., District of Columbia 20009, United States
    Recruiting
  • Encore Medical Research of Boynton Beach LLC /ID# 246833
    Boynton Beach, Florida 33436-7245, United States
    Recruiting
  • Gulf Coast Clinical Research Center /ID# 230020
    Fort Myers, Florida 33912, United States
    Recruiting
  • Sarkis Clinical Trials /ID# 227956
    Gainesville, Florida 32607, United States
    Completed

    Not enrolling at this site — choose another above.

  • Northwest Florida Clinical Research Group, LLC /ID# 231069
    Gulf Breeze, Florida 32561-4495, United States
    Completed

    Not enrolling at this site — choose another above.

  • AGA Clinical Trials /ID# 230554
    Hialeah, Florida 33012, United States
    Recruiting
  • Encore Medical Research /ID# 245682
    Hollywood, Florida 33021, United States
    Recruiting
    • Site Coordinator · Contact+1-954-400-1725
  • Advanced Research Institute of Miami /ID# 230292
    Homestead, Florida 33030-4613, United States
    Completed

    Not enrolling at this site — choose another above.

  • Auzmer Research /ID# 239251
    Lakeland, Florida 33813-2768, United States
    Completed

    Not enrolling at this site — choose another above.

  • Columbus Clinical Services, Llc /Id# 230880
    Miami, Florida 33125, United States
    Recruiting
  • My Preferred Research LLC /ID# 227886
    Miami, Florida 33155, United States
    Recruiting
  • Neurology & Pain Medicine /ID# 240168
    Miami, Florida 33186-7661, United States
    Completed

    Not enrolling at this site — choose another above.

  • Medical Research Group of Central Florida /ID# 231632
    Orange City, Florida 32763, United States
    Recruiting
  • Clinical Associates of Orlando, LLC /ID# 272619
    Orlando, Florida 32819, United States
    Recruiting
  • Suncoast Clinical Research - Palm Harbor /ID# 229337
    Palm Harbor, Florida 34684, United States
    Completed

    Not enrolling at this site — choose another above.

  • FWD Clinical Research - Spring Hill /ID# 229815
    Spring Hill, Florida 34609-5692, United States
    Recruiting
  • University of South Florida- Neuroscience Institute /ID# 229324
    Tampa, Florida 33613, United States
    Recruiting
  • Encore Medical Research - Weston /ID# 246809
    Weston, Florida 33331, United States
    Recruiting
  • Pediatric Neurology and Epilepsy Specialists /ID# 229967
    Winter Park, Florida 32789-7111, United States
    Recruiting
  • Treken Primary Care /ID# 240586
    Atlanta, Georgia 30315, United States
    Completed

    Not enrolling at this site — choose another above.

  • Rare Disease Research /ID# 231046
    Atlanta, Georgia 30318-2512, United States
    Recruiting
  • Clinical Integrative Research Center of Atlanta (CIRCA) /ID# 231134
    Atlanta, Georgia 30328, United States
    Recruiting
  • Coastal Georgia Child Neurology /ID# 231409
    Brunswick, Georgia 31520-1601, United States
    Recruiting
  • CenExcel iResearch LLC /ID# 227903
    Decatur, Georgia 30030, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research - Savannah. /ID# 228992
    Savannah, Georgia 31406, United States
    Recruiting
  • Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 231738
    Stockbridge, Georgia 30281, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research - Boise /ID# 231871
    Meridian, Idaho 83642, United States
    Recruiting
  • Chicago Headache Center & Research Institute /ID# 248625
    Chicago, Illinois 60657, United States
    Recruiting
    • Site Coordinator · Contact(773-935-1000)
  • Ascension Saint Alexius /ID# 275261
    Hoffman Estates, Illinois 60169, United States
    Recruiting
  • Accellacare - McFarland Clinic /ID# 229789
    Ames, Iowa 50010, United States
    Recruiting
  • College Park Family Care Center Overland Park /ID# 231456
    Overland Park, Kansas 66210-2761, United States
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Associates Midwest, LLC /ID# 274315
    Overland Park, Kansas 66214, United States
    Recruiting
  • Psychiatric Associates /ID# 230872
    Overland Park, Kansas 66221, United States
    Completed

    Not enrolling at this site — choose another above.

  • Alliance For Multispeciality Research - Wichita East /ID# 234126
    Wichita, Kansas 67207, United States
    Recruiting
  • University of Kentucky Chandler Medical Center /ID# 230827
    Lexington, Kentucky 40536, United States
    Recruiting
  • Pharmasite Research, Inc. /ID# 227908
    Baltimore, Maryland 21208, United States
    Recruiting
  • Minneapolis Clinic of Neurology - Burnsville /ID# 232551
    Burnsville, Minnesota 55337-6732, United States
    Recruiting
  • MediSync Clinical Research Hattiesburg Clinic /ID# 233326
    Petal, Mississippi 39465-2932, United States
    Completed

    Not enrolling at this site — choose another above.

  • Proven Endpoints LLC /ID# 239513
    Ridgeland, Mississippi 39157, United States
    Recruiting
  • Sharlin Health and Neurology /ID# 229523
    Ozark, Missouri 65721, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cognitive Clinical Trials (CCT) - Papillion /ID# 232552
    Papillion, Nebraska 68046-4131, United States
    Recruiting
  • Healthy Perspectives - Innovative Mental Health Services, PLLC /ID# 230312
    Nashua, New Hampshire 03060-3483, United States
    Recruiting
  • Hunterdon Neurology /ID# 245648
    Annandale, New Jersey 08801-3127, United States
    Completed

    Not enrolling at this site — choose another above.

  • Goryeb Childrens Hospital /ID# 229507
    Morristown, New Jersey 07960, United States
    Recruiting
  • CVS HealthHUB - Runnemede /ID# 234233
    Runnemede, New Jersey 08078-1034, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dent Neurologic Institute - Amherst /ID# 231182
    Amherst, New York 14226, United States
    Recruiting
  • Duplicate_Bioscience Research /ID# 232159
    Mount Kisco, New York 10549-3028, United States
    Completed

    Not enrolling at this site — choose another above.

  • Modern Migraine MD /ID# 258081
    New York, New York 10001, United States
    Completed

    Not enrolling at this site — choose another above.

  • North Suffolk Neurology /ID# 230956
    Port Jefferson Station, New York 11776-3387, United States
    Completed

    Not enrolling at this site — choose another above.

  • SUNY Upstate Medical University /ID# 239898
    Syracuse, New York 13210, United States
    Recruiting
  • CVS HealthHUB - Charlotte /ID# 239530
    Charlotte, North Carolina 28210-8905, United States
    Completed

    Not enrolling at this site — choose another above.

  • Onsite Clinical Solutions - Don Lochman Lane - Charlotte /ID# 282834
    Charlotte, North Carolina 28277, United States
    Recruiting
  • OnSite Clinical Solutions - Ninth Ave Drive North East - Hickory /ID# 227994
    Hickory, North Carolina 28601, United States
    Completed

    Not enrolling at this site — choose another above.

  • Patient Priority Clinical Sites, LLC /ID# 238485
    Cincinnati, Ohio 45215-2123, United States
    Recruiting
  • University Of Cincinnati Medical Center /ID# 231199
    Cincinnati, Ohio 45219, United States
    Recruiting
  • Cincinnati Childrens Hospital Medical Center /ID# 244689
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Headache Center of Hope /ID# 242645
    Cincinnati, Ohio 45236-1875, United States
    Recruiting
  • Centricity Research Columbus /ID# 231181
    Columbus, Ohio 43213, United States
    Recruiting
    • Site Coordinator · Contact614 501 6164
  • CincyScience /ID# 230046
    West Chester, Ohio 45069, United States
    Recruiting
  • IPS Research Company /ID# 227961
    Oklahoma City, Oklahoma 73106, United States
    Completed

    Not enrolling at this site — choose another above.

  • Providence Brain and Spine Institute /ID# 231607
    Portland, Oregon 97225-6625, United States
    Recruiting
  • Children's Hospital of Philadelphia - Main /ID# 232487
    Philadelphia, Pennsylvania 19104-4319, United States
    Recruiting
  • Frontier Clinical Research - Scottdale /ID# 231913
    Scottdale, Pennsylvania 15683, United States
    Recruiting
  • Frontier Clinical Research - Smithfield /ID# 231912
    Smithfield, Pennsylvania 15478, United States
    Recruiting
  • Coastal Pediatric Research /ID# 238616
    Charleston, South Carolina 29414-5834, United States
    Completed

    Not enrolling at this site — choose another above.

  • Tribe Clinical Research LLC /ID# 230422
    Greenville, South Carolina 29607-4021, United States
    Recruiting
  • Duplicate_Premier Neurology, P.C. /ID# 227999
    Greer, South Carolina 29650, United States
    Completed

    Not enrolling at this site — choose another above.

  • Access Clinical Trials, Inc. /ID# 228002
    Nashville, Tennessee 37203, United States
    Recruiting
  • UT Health Austin at Dell Children's Neurology Clinic /ID# 244266
    Austin, Texas 78723-3079, United States
    Recruiting
  • Austin Regional Clinic - ARC Four Points /ID# 276301
    Austin, Texas 78726, United States
    Recruiting
  • BioBehavioral Research of Austin /ID# 230529
    Austin, Texas 78759, United States
    Completed

    Not enrolling at this site — choose another above.

  • Velocity Clinical Research, Austin /ID# 230557
    Austin, Texas 78759, United States
    Recruiting
  • Tekton Research - Beaumont /ID# 231207
    Beaumont, Texas 77706-3067, United States
    Completed

    Not enrolling at this site — choose another above.

  • Relaro Medical Trials /ID# 239642
    Dallas, Texas 75243, United States
    Recruiting
  • Cedar Health Research /ID# 228003
    Dallas, Texas 75251-2202, United States
    Recruiting
  • Epic Medical Research - DeSoto /ID# 274314
    DeSoto, Texas 75115, United States
    Recruiting
  • 3A Research - East El Paso /ID# 239193
    El Paso, Texas 79925-7945, United States
    Completed

    Not enrolling at this site — choose another above.

Showing the first 100 of 129 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for May 2027, 64 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 64 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Nov 18, 2021
StartActual
Jan 13, 2022
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05125302
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Jan 13, 2022
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 14, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion